Another prediction RIGHT ON THE MONEY.
So much for Jetman/Arthurs1/Censored/Pvance criticism.
Arthur you are such a clown. Nobody is fooled by you. My answers are dead on backed up by solid mathematical calculations. While I understand that is beyond your comprehension (you know, doing the whole due diligence thing, research, etc.) you are a joke pretending you are multiple people. I guess that is what it is like to have nobody on your side.
You can't even be consistent. You criticize the company and CEO but come out with a monster target of more than $1,000/share. You can't even lie consistently.
You are pathetic.
You are really showing yourself off bad YG. I have never admitted anything and I gave you valuable info. Your answers are flimsy, and you've really nothing to say except to regurgitate what you've been fed by Mr. Beer et al. No sheer bitternes or hatred, I do think that Mr. Beer has had the opportunity to take a few liberties and he finally pushed to where he got himself handcuffed. I don't think you can really argue the info I posted because you don't know enough to do it. We'll see how the market over time sees the "huge" potential of this company. t
Jetman, also known as Arthurs1, also known as Censored, also known as AdamWang, also known as PVance, and many others, admitted he shorted back at $15, were forced to cover at $60 after losing his life savings and now he claims he can't retire because of his short-selling losses on AEGR.
Now he claims he has no position in AEGR whatsoever, and is here pestering others out of sheer bitterness and hatred.
Same calculations, same outlook, same result. I remember having this argument with Censored/Arthur/Jetmanbash/AdamWang back at $30 and $40 / share.
Wow, for someone pretending to be expecting a 10x increase (your target of $1,095) you sure are pretty negative on the company's outlook.
He would ask how are shorts are doing, I wonder how his long for an additional 100K is doing. In reality we could be looked at as helping him.....but NOOOO we're bad people A1 because we haven't bought into the 400K generous gift that Mr. Beer has supplied each and every HoF patient. Especially nice how he generously raised the price to help them out as he gets tears in his eyes while talking about the lethal LDL going through their bodies every day. Also impressive is the two in row annual announcement of the annual FH day. I'm sure he celebrated at the Waldorf Astoria for charity measures. t
All info posted has been accumulated over a decade. You might want to look at some of your dogmatic views in regards to no competition, how superior the MTP inhibitor is etc. If not....oh well you'll find out down the road. My new target price for AEGR(like Mr. Beer, metric not disclosed) is 1095. t
As John McEnroe said, 'You can't be serious.' $100 billion dollar company with one 20 year old drug held together with a paper-mach numbers patent. Maybe AEGR can buyout MRK then and have a real pipeline. t
The combination of these two drugs in the right patient, Kynamro, and a drug for Lp(a) could both cost less than juxta by itself and certainly much less than juxta plus Aphereses. One shot once a week with both, no diarrhea, no needle pokes for Aphereses, no worries about infections from Aphereses, and no worries about malabsorption syndromes, no time wasted every week or two in regards to Aphereses. t
The basic mechanism of action of this drug is along the lines of abetalipoproteinemia. A big risk for those patients is sudden deafness from Vitamin E deficiency. So as you can hopefully see this isn't just a big brother to statins. And unlike statins where you don't really ever have to check liver enzymes, with juxta you will always have to. t
No offense, and nobody is perfect, but your last statement is a perfect example of how the company has been able to pull this off. Many people think that it is just a big strong statin and you have to watch the liver enzymes too. Part of why Mr. Beer got that hand slap....that could hurt more eventually than people realize is his portraying that. At least to a certain degree. If you watch a Cialis commercial you're going to get more fright out of that than with a Mr. Beer talk. That is because unlike the Cialis commercial, when he does a nationwide commercial he doesn/t/hasn't yet put in those caveats like the Cialis commercials are required to do. Also, many, many people think that juxta is safer than the competitor when in fact the competitor has data that shows that after about seven months peoples' liver enzymes go back to normal, juxta can't say that. The other biggy is that small intestinal fat build-up, the competitor does not do that, the competitor doesn't lower your HDL like juxta does either, in fact it raises about 10% on average. You then come down to the famous argument a pill vs. a shot. However, if you have to keep on moving the doseages of juxta up or down depending on liver enzyme elevations, and tolerance to diarrhea you are going to have to be rechecking the blood much more frequently to reassess you results. No physician is going to make a doseage adjustment on a REMS drug without checking results of a change that the physician themselves are responsible for. Throw in the fact you will need to continue to watch for malabsortion syndrome for deficiencies in fat soluble vitamins, minerals, and other important substances and you're going to be having a lot more needle sticks than people realize. The basic mechanism of action of this drug is along the lines of abetalipoproteinemia.
Are all of those profits going to go into a pediatric study? Then there is their foray into treating patients with FCS. They originally thought that they would do that because they were convinced that the drug would work based on a one patient experience with a physician from Harvard placing a patient with FCS on the MTP inhibitor about 14 years ago. Again a far cry from even the 23 patient study, and profits will vanish if this is attempted. Now with their present competitor having a vastly superior product for that indication, and another drug from NVS also in the pipeline that places this possibility of the FCS indication down below 1% IMO.
You then have the patent issue. They do have a patent on the dosing. Not much real medicine knowledge to protect there. I predict in about three years someone like TEVA is going to challenge that patent. A company of size will play "patent poker." Someone can counter with that AEGR could just pay them to back off which has become common practice. AZN and generic makers under federal indictment for that very thing and the FDA is moving to most likely make that illegal. A paper-mach company this AEGR. The argument can also be that is the job of the CEO to really promote your company. However, when the CEO has gone to the extreme that he is attracting negative attention to the company, and he has to watch every word he says know he has made himself much less effective in trying to obtain that goal With a huge distraction, possibly a fine, and making yourself much less useful.....maybe your usefulness has come to an end?! t
Some guy brought up the analogy of AEGR being like other orphan drug makers and how they grew their population. No comparison iMO:
The huge difference between AEGR and the companies you listed is that these companies are able to actually get MORE NEW indications for their products. QCOR has about nine different uses for their drug and just this year expanded that out with another. They have even been able to go "mainstream" with some patients who fail other MS treatments to be on their drug. Look at ALXN, they also have about nine different indications for their drug. In regards to JAZZ, their drug is reliant on patients with phenotypical problems that need/could be discovered. A huge difference when comparing that to someone with a GENETIC problem. It is said that in pro-sports that a team is only as good as its management, and this is biotech not sports but the rule still applies IMO. If you go to the website for AEGR you see all over the philosophy of the company as per Mr. Beer. They are in the business to treat orphan diseaseS. With an S.....what other diseases are they going to tackle in the next five to seven years? I know they are working on it. Let's see how that is going. Look at the pipeline that they no longer publish. It is one drug, another MTP inhibitor that I believe was purchased to reduce the possibility of competition down the road. Well maybe they'll discover something in the lab.....they have no discovery lab. Well they say they are going for the pediatric use of juxtapid under development of NEW products. How will they pull that off? Mr. Beer got extremely lucky in regards to how the FDA handled their 23 patient study in adults. That won't happen again in children. That study will end up costing in excess of $70 million IMO. Well let's see when they can fund something like that. Mr. Beer has already warned shareholders don't expect to see any profits until late 2014, early 2015. Part I
Metablomics called back with one question, and one statement. Question was, Where did you get that? The statement was DON'T ever use it. So you see, Mr. Beer owes a lot to the FDA, he fell "victim" to the old saying, 'if you give them an inch they'll want a mile.'. t